Search alternatives:
significant estimates » significant time (Expand Search), significant rates (Expand Search)
estimates decrease » estimates decreased (Expand Search), estimated decrease (Expand Search), estimated release (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 21 - 40 results of 8,537 for search '(( significant estimates decrease ) OR ( significant ((largest decrease) OR (larger decrease)) ))', query time: 0.36s Refine Results
  1. 21
    The distribution of <i>Giardia duodenalis</i> assemblages in domestic and wild populations of nonhuman mammalian species with a larger number of isolates.

    The distribution of <i>Giardia duodenalis</i> assemblages in domestic and wild populations of nonhuman mammalian species with a larger number of isolates. by Kareem Hatam-Nahavandi (7384790)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 22
    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15.

    Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

    Published 2019
    Save to List
    Saved in:
  3. 23
    Decrease of injuries.

    Decrease of injuries. by Petr Fulin (8380320)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 24
    Estimation results of model (3).

    Estimation results of model (3). by Jing-hua Yin (13007541)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 25
    Estimation results of model (1).

    Estimation results of model (1). by Jing-hua Yin (13007541)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 26
    Estimation results of model (2).

    Estimation results of model (2). by Jing-hua Yin (13007541)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 27
    Estimation results of model (4).

    Estimation results of model (4). by Jing-hua Yin (13007541)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 28
    Error estimation of path analysis.

    Error estimation of path analysis. by Jing-hua Yin (13007541)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 29
    Example of predicted effects of choice bundling on preference for larger, later rewards (LLRs) over smaller, sooner rewards (SSRs).

    Example of predicted effects of choice bundling on preference for larger, later rewards (LLRs) over smaller, sooner rewards (SSRs). by Jeffrey S. Stein (11689918)

    Published 2021
    Save to List
    Saved in:
  10. 30
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 31
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 32
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 33
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 34
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 35
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 36
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 37
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 38
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 39
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 40
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: